TCRX — Tscan Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.21m
- -$54.17m
- $10.33m
Brief: TScan Therapeutics Announces Upcoming Trial In Progress Poster Presentation
U.S. STOCKS ON THE MOVE-Coherent, Copper miners, US banks
U.S. STOCKS ON THE MOVE-Ulta Beauty, Paramount Global, Microsoft
U.S. STOCKS ON THE MOVE-Marvell Technology, Tilray, Workday
U.S. STOCKS ON THE MOVE-Ford Motor, Gap, Moderna
TScan Therapeutics drops on pricing $140 mln stock offering
Brief: TScan Therapeutics Announces Pricing Of 22.9 Million Shares Of Its Voting Common Stock At A Public Offering Price Of $2.00 Per Share
Brief: Tscan Therapeutics Announces Launch Of Proposed Public Offering
Brief: TScan Therapeutics Appoints Gavin MacBeath As Chief Executive Officer
Brief: Tscan Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Airbnb, Y-mAbs Therapeutics, Neuronetics
TScan Therapeutics surges on licensing deal with Amgen
U.S. STOCKS ON THE MOVE-Boeing, TScan Therapeutic, Under Armour
TScan Therapeutics surges on licensing deal with Amgen
Brief: Amgen and TScan Therapeutics Announce Collaboration
Brief: TScan Therapeutics Appoints Barbara Klencke To Its Board
TScan Therapeutics CEO steps down, shares fall
Brief: Tscan Therapeutics Announces CEO Transition
TScan Therapeutics rise after starting patient dosing in blood cancer drug trial